Wang Fenghua, Bie Lili
Institute of Physical Education, Xinjiang Normal University, Urumqi, Xinjiang 830054, P.R. China.
Department of Blood Component Preparation, Henan Red Cross Blood Center, Zhengzhou, Henan 450000, P.R. China.
Exp Ther Med. 2018 Feb;15(2):1879-1885. doi: 10.3892/etm.2017.5614. Epub 2017 Dec 12.
The aim of the present study was to investigate the use of GATA-3 markers in the detection of hematologic disorders in children. In total, 35 pediatric patients diagnosed with blood disease and treated in Henan Red Cross Blood Center from January 2014 to June 2015 were selected for the observation group. Another 32 healthy children were selected for the control group. The differences in the GATA-3 mRNA expression levels between the control and observation groups were detected via reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The differences in the GATA-3 protein expression levels were detected via enzyme-linked immunosorbent assay (ELISA) and western blot analysis. Compared with those in the healthy children, the mRNA expression levels of GATA-3 in patients with hematologic malignancies, acute lymphoblastic leukemia, myeloproliferative disorder, acute non-lymphocytic leukemia or thrombocytopenic purpura were significantly higher, and there were statistically significant differences between the groups (P<0.05). The results of ELISA showed that the GATA-3 protein expression levels in patients with hematologic malignancies (241.3±42.6 µg/l), acute lymphoblastic leukemia (196.3±21.6 µg/l), myeloproliferative disorder (284.2±45.1 µg/l), acute non-lymphocytic leukemia (269.3±31.4 µg/l) or thrombocytopenic purpura (272.1±39.1 µg/l) were significantly higher than those in healthy subjects (69.3±15.2 µg/l). The results of western blot analysis were consistent with those of ELISA. Based on our results, the expression levels of GATA-3 in healthy children and pediatric patients with blood diseases exhibit significant differences, and can be used as important markers for the clinical diagnosis of blood diseases in children.
本研究的目的是探讨GATA-3标志物在儿童血液系统疾病检测中的应用。选取2014年1月至2015年6月在河南红十字血液中心诊断为血液病并接受治疗的35例儿科患者作为观察组。另选取32例健康儿童作为对照组。通过逆转录-定量聚合酶链反应（RT-qPCR）检测对照组和观察组之间GATA-3 mRNA表达水平的差异。通过酶联免疫吸附测定（ELISA）和蛋白质印迹分析检测GATA-3蛋白表达水平的差异。与健康儿童相比，血液系统恶性肿瘤、急性淋巴细胞白血病、骨髓增殖性疾病、急性非淋巴细胞白血病或血小板减少性紫癜患者的GATA-3 mRNA表达水平显著升高，且组间差异具有统计学意义（P<0.05）。ELISA结果显示，血液系统恶性肿瘤（241.3±42.6 μg/l）、急性淋巴细胞白血病（196.3±21.6 μg/l）、骨髓增殖性疾病（284.2±45.1 μg/l）、急性非淋巴细胞白血病（269.3±31.4 μg/l）或血小板减少性紫癜（272.1±39.1 μg/l）患者的GATA-3蛋白表达水平显著高于健康受试者（69.3±15.2 μg/l）。蛋白质印迹分析结果与ELISA结果一致。基于我们的结果，健康儿童和患有血液疾病的儿科患者中GATA-3的表达水平存在显著差异，可作为儿童血液疾病临床诊断的重要标志物。
